Search

BI Access to Healthcare Strategy_Availability

Boehringer Ingelheim aspires to be a leader in ensuring improved access by delivering More Health to humans, animals and communities around the world. Read more about our holistic approach, based on partnerships and local empowerment.

Oncology

We are looking for new early-science collaborations and invite you to join our expanding community of innovation partners in oncology.

Partnering in Retinal Health

Our partnering interests in retinal diseases offer opportunities for collaboration to complement our pipeline and advance treatment and delivery.

Partnership Boehringer Ingelheim Lifebit health data

Boehringer Ingelheim and Lifebit announce partnership to capture transformational value of health data

Partnering-with-google-in-quantum-computing

New cooperation with Google explores the potentials of quantum computing for pharma R&D.

collaboration-LIBD

Boehringer Ingelheim and The Lieber Institute for Brain Development collaborate on centrally acting COMT inhibitors in neuropsychiatric disorders

Big molecules - Huge potential | Bioxcellence | Boehringer Ingelheim

Explore the potential of big molecules with BioXcellence, offering advanced biopharmaceutical production services to unlock new possibilities in healthcare.

AUROBAC's Strategy & Pipeline Against Severe Infections & Resistance

AUROBAC THERAPEUTICS presents strategy and growing pipeline to tackle severe infections and antimicrobial resistance

1885-1948: Innovative beginnings

The Boehringer Ingelheim history from its start in 1885 to 1948, with milestones and important products

Drug Discovery Process

“Rapid progress towards clinical candidates”

Boehringer Ingelheim forms a joint venture to create the next generation of antimicrobials.

Ruminant parasite control in a nutshell

An exclusive drug-based approach to fight worms is dying. Dr. Ray Kaplan, from Georgia University, explains five things you need to know.

License to develop new fibro-inflammatory disease treatments

Partnership canine oncology

The collaboration will focus on identifying new molecules to target cancers in dogs. Small molecules could provide superior disease control.

SIRPα antagonist

EURORDIS Award

EURORDIS has selected Boehringer Ingelheim for the first time as recipient of the prestigious Black Pearl Award 2020

Partnership with IBM to accelerate new antibody therapies

Boehringer Ingelheim collaborates with IBM to advance generative AI and foundation models for therapeutic antibody development

1990-2023: Value through Innovation

The Boehringer Ingelheim history from 1990 to 2023, with milestones

History of Cats

From the African wildcat to the domesticated house cat of today, the fascinating journey and history of the cat touches almost all corners of the world.

Partnering in Central Nervous System Diseases

We are looking for new early-science collaborations. Join our expanding community of innovation partners in central nervous system diseases.

Green Chemistry

Green Chemistry is critical for us as it balance the long-term sustainability of business, society, and the environment.

digital_leader_award_2020

Boehringer Ingelheim wins first place in the "STRATEGY" category of the Digital Leader Award

Partnership to Develop Urea Cycle Disorders Therapy

Boehringer Ingelheim Partners with Thoeris to Investigate a Novel Approach to Treat Urea Cycle Disorders

Option to Acquire Trutino Biosciences

Why cancer care is personal for us

At Boehringer Ingelheim, we have made a generational commitment to transforming cancer care, with the ultimate goal of curing a range of cancers.

About Us

Human Health

Animal Health

Science & Innovation

Partnering

Careers